News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Corgenix Medical Corporation (CONX) Files Concurrent de novo 510(k) Pre-Market Notification For FDA Clearance Of Its Hyaluronic Acid (HA) Test Kit


11/12/2013 9:43:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today it has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for its Hyaluronic Acid (HA) ELISA Test Kit.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES